FDA Approves IND for FCR001, a Potential Treatment for Diffuse SSc
Biotechnology company Talaris Therapeutics, Inc. submitted an Investigational New Drug (IND) application to the FDA for their novel cell therapy treatment FCR001. As per a press release, the FDA…